查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1880418

药物定序市场预测至2032年：按治疗领域、药物类型、应用、最终用户和地区分類的全球分析

Drug Repurposing Market Forecasts to 2032 - Global Analysis By Therapeutic Area, Drug Type, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的一项研究，全球药物定序市场预计到 2025 年价值 4.6 亿美元，预计到 2032 年将达到 14 亿美元，在预测期内以 17.0% 的复合年增长率增长。

药物定序是指发掘已获已通过核准或正在研发的药物的其他医疗用途。透过利用现有药物的安全性和作用机制知识来识别新的疾病标靶，可以降低研发成本、缩短开发週期并最大限度地减少安全性方面的不确定性。因此，药物重定位在快速提供有效治疗方面发挥重要作用，尤其是在癌症、神经系统疾病和感染疾病等治疗难度较高的领域。

慢性病负担日益加重

药物定序因其比传统药物发现和开发速度更快、成本更低而备受关注。随着人口老化和诊断技术的进步，已开发国家和新兴国家对新治疗途径的需求日益增长。再利用药物正越来越多地被纳入个人化医疗策略，有助于改善患者预后并缩短治疗週期。计算生物学和人工智慧驱动的筛检的进步正在加速现有化合物新用途的发现。慢性疾病负担的日益恶化是推动药物定序市场扩张的主要因素。

经济奖励有限

仿单标示外用药的专利保护通常较弱，降低了长期盈利潜力。法规结构复杂，新适应症的药物核准路径也可能不明朗。缺乏强而有力的报销和奖励机制，小规模公司难以将资源投入仿单标示外计划。缺乏强有力的资金支持会减缓创新，并抑制对细分治疗领域的投资。因此，有限的经济奖励仍是阻碍因素市场成长的主要因素。

罕见疾病治疗

药物定序为治疗罕见疾病和难治性疾病提供了独特的机会。由于传统药物研发的商业性吸引力较低，这些疾病往往缺乏有效的治疗方法。再利用的药物可以绕过漫长的药物研发阶段，使服务不足的患者群体能够更快地获得治疗。监管机构也日益支持药物再利用，提供孤儿药认定和加速核准等奖励。基因组学和生物标记识别技术的进步，使得针对更罕见疾病的标靶药物再利用策略成为可能。对罕见疾病的日益关注，正在为市场拓展开闢新的途径。

新环境下的安全性和有效性问题

临床疗效会因患者人口统计学特征、剂量和疾病生物学特性而显着不同。监管机构要求进行广泛的测试，以确保药物再利用符合严格的安全标准。意外的副作用或疗效降低可能会削弱人们对再利用疗法的信心。这些风险可能导致商业化进程延迟，并增加製药公司的研发成本。因此，对安全性和有效性的担忧对药物定序市场构成持续的威胁。

新冠疫情的影响：

新冠疫情加速了人们对药物定序的兴趣，研究人员急需寻找即时的治疗方案。多种现有药物的抗病毒特性得到了评估，凸显了它们在紧急情况下重新利用的潜力。各国政府、学术界和产业界之间的全球合作得到加强，促成了快速的临床试验和紧急使用授权。然而，供应链中断和试验结果的不一致给药物的持续应用带来了挑战。疫情也凸显了建构具有韧性的法规结构和製定适应性强的研发策略的重要性。

预计在预测期内，肿瘤治疗领域将占据最大的市场份额。

预计在预测期内，肿瘤领域将占据最大的市场份额。癌症复杂的生物学特性和巨大的未满足治疗方法需求使其成为药物再利用的关键领域。现有药物正被评估用于新的肿瘤适应症，从而缩短研发时间和降低成本。医院和研究机构越来越多地采用再利用的肿瘤药物来拓展治疗选择。精准医疗和生物标记主导疗法的进步进一步推动了这一趋势。随着全球癌症发生率的持续上升，肿瘤领域仍然是药物定序的最大领域。

预计在预测期内，学术和研究机构板块的复合年增长率将最高。

预计在预测期内，学术和研究机构板块将实现最高成长率，因为这些机构在药物再利用的早期发现和检验中发挥关键作用。与製药公司和政府机构的合作计划正在拓展其研究能力。大学正利用运算建模和人工智慧的进步来加速药物再利用的研发进程。转化研究经费的不断成长也进一步推动了该板块的成长。

占比最大的地区：

预计亚太地区将在预测期内占据最大的市场份额。中国、印度和日本等国正大力投资医疗基础设施和药物研发。政府主导的措施正在推动本地药物开发和再利用策略，旨在降低成本。慢性病盛行率的上升和大规模的患者群体正在推动对价格合理的治疗方法的需求。学术合作和临床试验网络正在全部区域扩展，从而促进了药物的快速应用。

复合年增长率最高的地区：

预计北美地区在预测期内将呈现最高的复合年增长率。强劲的研发投入和先进的医疗基础设施为创新提供了沃土。美国和加拿大在人工智慧药物研发和精准医疗应用方面处于主导地位。 FDA等监管机构正在简化老药新核准流程，加速药物商业化进程。完善的健保体系和新治疗方法的高普及率进一步推动了市场成长。

免费客製化服务：

购买此报告的客户可以选择以下免费自订选项之一：

  • 公司概况
    • 对其他市场公司（最多 3 家公司）进行全面分析
    • 对主要企业进行SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户要求，提供主要国家的市场估算和预测以及复合年增长率（註：可行性需确认）。
  • 竞争基准化分析
    • 根据主要企业的产品系列、地理覆盖范围和策略联盟基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 原始研究资料
    • 次级研究资讯来源
    • 先决条件

第三章 市场趋势分析

  • 介绍
  • 司机
  • 抑制因素
  • 机会
  • 威胁
  • 应用分析
  • 终端用户分析
  • 新兴市场
  • 新冠疫情的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球药物定序市场（依治疗领域划分）

  • 介绍
  • 肿瘤学
  • 神经病学
  • 感染疾病
  • 心血管疾病
  • 自体免疫疾病与发炎性疾病
  • 罕见疾病
  • 代谢紊乱
  • 其他治疗领域

6. 全球药物定序市场（依药物类型划分）

  • 介绍
  • 小分子
  • 生物製药

7. 全球药物定序市场（依应用领域划分）

  • 介绍
  • 发现新的适应症
  • 线路延长
  • 处方变更和联合治疗
  • 其他用途

8. 全球药物定序市场（依最终用户划分）

  • 介绍
  • 製药和生物技术公司
  • 学术研究机构
  • 合约研究组织（CRO）
  • 医疗保健提供者
  • 其他最终用户

9. 全球药物定序市场（依地区划分）

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 亚太其他地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十章：重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与併购
  • 新产品上市
  • 业务拓展
  • 其他关键策略

第十一章 企业概况

  • Recursion Pharmaceuticals
  • Pfizer
  • Healx
  • NuMedii
  • BenevolentAI
  • BioXcel Therapeutics
  • Evotec SE
  • Rejuvenate Biomed
  • Exscientia
  • Melior Discovery
  • Insilico Medicine
  • Pharnext
  • Lantern Pharma
  • Standigm
  • Biovista
Product Code: SMRC32560

According to Stratistics MRC, the Global Drug Repurposing Market is accounted for $0.46 billion in 2025 and is expected to reach $1.40 billion by 2032 growing at a CAGR of 17.0% during the forecast period. Drug repurposing involves discovering additional medical applications for drugs that are already approved or under development. It leverages existing knowledge about a drug's safety and mechanism of action to find new disease targets. This strategy lowers research costs, shortens development timelines, and minimizes safety uncertainties. As a result, repurposing plays a crucial role in quickly delivering effective treatments, especially in challenging therapeutic fields such as cancer, neurological disorders, and infectious diseases.

Market Dynamics:

Driver:

Rising chronic disease burden

Drug repurposing is gaining traction as it offers faster and more cost-effective solutions compared to traditional drug development. With aging populations and improved diagnostic capabilities, the demand for novel treatment pathways is expanding across both developed and emerging economies. Repurposed drugs are increasingly being integrated into personalized medicine strategies, enhancing patient outcomes and reducing treatment timelines. Advances in computational biology and AI-driven screening are accelerating the identification of new uses for existing compounds. This rising chronic disease burden is therefore a major catalyst for the expansion of the drug repurposing market.

Restraint:

Limited financial incentives

Patent protection is often weaker for repurposed drugs, reducing the potential for long-term profitability. Regulatory frameworks can be complex, with unclear pathways for approval of drugs in new indications. Smaller firms struggle to allocate resources toward repurposing projects without strong reimbursement or incentive structures. The lack of robust financial backing slows innovation and discourages investment in niche therapeutic areas. Consequently, limited financial incentives remain a significant restraint on market growth.

Opportunity:

Orphan and rare disease treatment

Drug repurposing presents a unique opportunity in the treatment of orphan and rare diseases. These conditions often lack effective therapies due to limited commercial appeal for traditional drug development. Repurposed drugs can bypass lengthy discovery phases, offering faster access to treatments for underserved patient populations. Regulatory agencies are increasingly supportive, providing incentives such as orphan drug designations and expedited approval pathways. Advances in genomics and biomarker identification are further enabling targeted repurposing strategies for rare conditions. This growing focus on orphan and rare diseases is opening new avenues for market expansion.

Threat:

Safety and efficacy concerns in a new context

Clinical outcomes may vary significantly depending on patient demographics, dosage, and disease biology. Regulatory authorities demand extensive testing to ensure that repurposed drugs meet rigorous safety standards. Unexpected side effects or reduced effectiveness can undermine confidence in repurposed therapies. These risks can delay commercialization and increase development costs for pharmaceutical firms. As a result, safety and efficacy concerns represent a persistent threat to the drug repurposing market.

Covid-19 Impact:

The Covid-19 pandemic accelerated interest in drug repurposing as researchers sought immediate solutions for treatment. Several existing drugs were evaluated for antiviral properties, highlighting the potential of repurposing in emergency contexts. Global collaboration between governments, academia, and industry intensified, leading to rapid clinical trials and emergency authorizations. However, supply chain disruptions and inconsistent trial results created challenges for sustained adoption. The pandemic also emphasized the importance of resilient regulatory frameworks and adaptive R&D strategies.

The oncology segment is expected to be the largest during the forecast period

The oncology segment is expected to account for the largest market share during the forecast period. Cancer's complex biology and high unmet medical need make it a prime area for repurposed therapies. Existing drugs are being evaluated for new oncological applications, reducing development timelines and costs. Hospitals and research institutes are increasingly adopting repurposed oncology drugs to expand treatment options. Advances in precision medicine and biomarker-driven approaches are further supporting this trend. As cancer incidence continues to rise globally, oncology remains the largest segment in drug repurposing.

The academic & research institutes segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the academic & research institutes segment is predicted to witness the highest growth rate, due to these institutions play a critical role in early-stage discovery and validation of repurposed drugs. Collaborative projects with pharmaceutical companies and government agencies are expanding research capacity. Advances in computational modeling and AI are being leveraged by universities to accelerate repurposing pipelines. Increased funding for translational research is further boosting growth in this segment.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share. Countries such as China, India, and Japan are investing heavily in healthcare infrastructure and pharmaceutical R&D. Government initiatives are promoting local drug development and encouraging repurposing strategies to reduce costs. Rising chronic disease prevalence and large patient populations are driving demand for affordable therapies. Academic collaborations and clinical trial networks are expanding across the region, supporting rapid adoption.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR. Strong R&D investments and advanced healthcare infrastructure provide a fertile environment for innovation. The U.S. and Canada are leading in AI-driven drug discovery and precision medicine applications. Regulatory agencies such as the FDA are streamlining pathways for repurposed drugs, encouraging faster commercialization. Robust reimbursement systems and high adoption of novel therapies further support market growth.

Key players in the market

Some of the key players in Drug Repurposing Market include Recursion, Pfizer, Healx, NuMedii, Benevolent, BioXcel Th, Evotec SE, Rejuvenate, Exscientia, Melior Dis, Insilico Me, Pharnext, Lantern Ph, Standigm, and Biovista.

Key Developments:

In November 2025, Pfizer Inc. announced the successful completion of its acquisition of Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases. This strategic milestone represents more than a transaction it's a deliberate investment in the future of medicine.

In October 2024, Recursion and Google Cloud announced an expanded collaboration leveraging Google Cloud's technologies to support Recursion's drug discovery platform. This strategic partnership includes exploring generative AI capabilities, including Gemini models, to support the RecursionOS, drive improved search and access with BigQuery, and help scale compute resources.

Therapeutic Areas Covered:

  • Oncology
  • Neurology
  • Infectious Diseases
  • Cardiovascular Diseases
  • Autoimmune & Inflammatory Diseases
  • Rare Diseases
  • Metabolic Disorders
  • Other Therapeutic Areas

Drug Types Covered:

  • Small Molecules
  • Biologics

Applications Covered:

  • New Indications Discovery
  • Line Extension
  • Reformulation & Combination Therapy
  • Other Applications

End Users Covered:

  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • Contract Research Organizations (CROs)
  • Healthcare Providers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Drug Repurposing Market, By Therapeutic Area

  • 5.1 Introduction
  • 5.2 Oncology
  • 5.3 Neurology
  • 5.4 Infectious Diseases
  • 5.5 Cardiovascular Diseases
  • 5.6 Autoimmune & Inflammatory Diseases
  • 5.7 Rare Diseases
  • 5.8 Metabolic Disorders
  • 5.9 Other Therapeutic Areas

6 Global Drug Repurposing Market, By Drug Type

  • 6.1 Introduction
  • 6.2 Small Molecules
  • 6.3 Biologics

7 Global Drug Repurposing Market, By Application

  • 7.1 Introduction
  • 7.2 New Indications Discovery
  • 7.3 Line Extension
  • 7.4 Reformulation & Combination Therapy
  • 7.5 Other Applications

8 Global Drug Repurposing Market, By End User

  • 8.1 Introduction
  • 8.2 Pharmaceutical & Biotechnology Companies
  • 8.3 Academic & Research Institutes
  • 8.4 Contract Research Organizations (CROs)
  • 8.5 Healthcare Providers
  • 8.6 Other End Users

9 Global Drug Repurposing Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Recursion Pharmaceuticals
  • 11.2 Pfizer
  • 11.3 Healx
  • 11.4 NuMedii
  • 11.5 BenevolentAI
  • 11.6 BioXcel Therapeutics
  • 11.7 Evotec SE
  • 11.8 Rejuvenate Biomed
  • 11.9 Exscientia
  • 11.10 Melior Discovery
  • 11.11 Insilico Medicine
  • 11.12 Pharnext
  • 11.13 Lantern Pharma
  • 11.14 Standigm
  • 11.15 Biovista

List of Tables

  • Table 1 Global Drug Repurposing Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Drug Repurposing Market Outlook, By Therapeutic Area (2024-2032) ($MN)
  • Table 3 Global Drug Repurposing Market Outlook, By Oncology (2024-2032) ($MN)
  • Table 4 Global Drug Repurposing Market Outlook, By Neurology (2024-2032) ($MN)
  • Table 5 Global Drug Repurposing Market Outlook, By Infectious Diseases (2024-2032) ($MN)
  • Table 6 Global Drug Repurposing Market Outlook, By Cardiovascular Diseases (2024-2032) ($MN)
  • Table 7 Global Drug Repurposing Market Outlook, By Autoimmune & Inflammatory Diseases (2024-2032) ($MN)
  • Table 8 Global Drug Repurposing Market Outlook, By Rare Diseases (2024-2032) ($MN)
  • Table 9 Global Drug Repurposing Market Outlook, By Metabolic Disorders (2024-2032) ($MN)
  • Table 10 Global Drug Repurposing Market Outlook, By Other Therapeutic Areas (2024-2032) ($MN)
  • Table 11 Global Drug Repurposing Market Outlook, By Drug Type (2024-2032) ($MN)
  • Table 12 Global Drug Repurposing Market Outlook, By Small Molecules (2024-2032) ($MN)
  • Table 13 Global Drug Repurposing Market Outlook, By Biologics (2024-2032) ($MN)
  • Table 14 Global Drug Repurposing Market Outlook, By Application (2024-2032) ($MN)
  • Table 15 Global Drug Repurposing Market Outlook, By New Indications Discovery (2024-2032) ($MN)
  • Table 16 Global Drug Repurposing Market Outlook, By Line Extension (2024-2032) ($MN)
  • Table 17 Global Drug Repurposing Market Outlook, By Reformulation & Combination Therapy (2024-2032) ($MN)
  • Table 18 Global Drug Repurposing Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 19 Global Drug Repurposing Market Outlook, By End User (2024-2032) ($MN)
  • Table 20 Global Drug Repurposing Market Outlook, By Pharmaceutical & Biotechnology Companies (2024-2032) ($MN)
  • Table 21 Global Drug Repurposing Market Outlook, By Academic & Research Institutes (2024-2032) ($MN)
  • Table 22 Global Drug Repurposing Market Outlook, By Contract Research Organizations (CROs) (2024-2032) ($MN)
  • Table 23 Global Drug Repurposing Market Outlook, By Healthcare Providers (2024-2032) ($MN)
  • Table 24 Global Drug Repurposing Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.